Orthostatic hypotension is a phenomenon commonly encountered in a cardiologist's clinical practice that has significant diagnostic and prognostic value for a cardiologist. Given the mounting evidence associating cardiovascular morbidity and mortality with orthostatic hypotension, cardiologists will play an increasing role in treating and managing patients with orthostatic hypotension.
INTRODUCTION
Orthostatic hypotension is a problem cardiologists commonly encounter in the clinical setting. The cause can be as simple and reversible as overzealous diuresis, or as troublesome as autonomic nervous system failure secondary to long-standing diabetes mellitus. Regardless of the cause, orthostatic hypotension is the second most common cause of syncope, which is perhaps the most immediately hazardous and dramatic hemodynamic consequence of orthostatic hypotension. Syncope leads to hospital admissions in greater than 50% of those older than 80 years of age [1,2 && ]. To complicate matters, severe hypertension (HTN) in the supine position (supine HTN) is a phenomenon observed in over half of neurogenic orthostatic hypotension (nOH) cases, and regulating blood pressures (BP) in these two extremes can be especially challenging, warranting the expertise of a cardiovascular specialist in many cases [3 & ].
Orthostatic hypotension is associated with significant cardiovascular morbidity and mortality. Not only does orthostatic hypotension predicts coronary events, congestive heart failure (CHF), and cardiovascular mortality, the concomitant development of orthostatic hypotension in patients with diabetes mellitus and CHF portends a much poorer prognosis in these disease states [4] [5] [6] [7] [8] . A cardiovascular explanation for this association is unclear but may involve structural remodeling of the heart (increased left ventricular hypertrophy, worsening diastolic dysfunction) in orthostatic hypotension patients [9] .
Understanding the pathophysiology and treatment options of orthostatic hypotension can help the cardiologist delineate the cause of syncope, treat supine HTN, and also enable them to provide better cardiovascular care to those with orthostatic hypotension, whatever the cause may be.
NORMAL PHYSIOLOGY AND DEFINITIONS

Normal physiology
In healthy individuals, assumption of an upright position results in an almost immediate redistribution of up to 1 l of blood into the lower extremities and the splanchnic circulation (Fig. 1) . The resulting decrease in venous return and, consequently, cardiac output is detected by carotid and aortic baroreceptors, causing a surge of catecholamine release from the sympathetic nervous system to both increase cardiac contractility, increase heart rate (HR), and most importantly, produce peripheral vasoconstriction. If this reflex is orchestrated flawlessly, the SBP should decrease by no more than 10 mmHg, the DBP should very slightly increase, and there should only be a modest increase in HR by 10-20 beats/min (bpm) [10 & ].
Definition
Orthostatic hypotension is a hemodynamic finding observed during standing (orthostasis) consisting of either a 20 mmHg drop in SBP or 10 mmHg drop in DBP when assuming an upright position after at least 5-min supine [10 & ]. In cases of supine HTN (defined as SBP >150 mmHg or DBP >90 mmHg), a drop of 30 mmHg of SBP or 15 mmHg of DBP must be present [10 & ]. Orthostatic hypotension itself does not imply a specific pathophysiology. nOH is a subtype of orthostatic hypotension in which there is evidence of an autonomic neuropathy, with an inability to vasoconstrict adequately to maintain adequate vascular resistance [10 & ]. Often the physiological reflex tachycardia is blunted or absent in patients with nOH.
Neurogenic versus nonneurogenic orthostatic hypotension
Orthostatic hypotension can be broadly classified into two categories: nOH or nonneurogenic orthostatic hypotension (non-nOH) [1] . In nOH, the normal physiologic BP and HR response is either severely dysfunctional or outright absent. In conditions such as multiple system atrophy (MSA), pure autonomic failure, dementia with Lewy bodies, or Parkinson's disease, there is a characteristic profound deficiency in norepinephrine release during standing in over 75% of patients [11, 12] . This deficiency in norepinephrine release reflects an inability of sympathetic vasoconstrictor neurons to fire adequately, which is responsible for the lack of peripheral vasoconstriction and consequent hypotension
KEY POINTS
Orthostatic hypotension is defined as a drop in SBP of 20 mmHg or DBP of 10 mmHg within 3 min of standing.
There are both reversible and irreversible causes of orthostatic hypotension, and reversible causes are often iatrogenic (medications, hypovolemia).
Droxidopa and midodrine are both short-acting peripheral vasoconstrictors that are FDA approved to treat types of orthostatic hypotension.
Supine HTN is a common phenomenon seen in orthostatic hypotension (up to 50%).
Management of supine HTN requires using short-acting drugs and requires approaches to reduce BP only at night. FIGURE 1. Normal physiologic reflex and common pathologic or iatrogenic mechanisms causing orthostatic hypotension. Key components of the normal physiologic reflex in rounded rectangles and arrows. Trapezoid boxes are common pathologic or iatrogenic mechanisms which cause or contribute to orthostatic hypotension. Bolts indicate specific areas in the normal physiologic reflex that are affected by these mechanisms. AF, autonomic failure; BB, bblockers; BV, blood volume; CCB, calcium channel blockers; PVR, peripheral vascular resistance; VD, vasodilators.
( Fig. 1) . Peripheral neuropathies such as vitamin B deficiencies, exposure to heavy metals, amyloidosis, certain chemotherapeutic agents, and most importantly diabetes mellitus, which is the most common cause of nOH peripherally, can also suppress the normal BP and HR response to standing [6, 13] . Not surprisingly, diabetic patients with orthostatic hypotension have higher hemoglobin A1c levels when compared with diabetic patients without orthostatic hypotension [14] . Non-nOH causes of orthostatic hypotension are often reversible and involve conditions that overwhelm a well-functioning autonomic system with an intact sympathetic nervous system response to standing. These conditions commonly include profound hypovolemia, medication effects, and severe systolic CHF [1]. Intense fluid restriction, overdiuresis, and hemorrhage are all common clinical scenarios, cardiologists encounter, that can cause hypovolemia to the point orthostatic hypotension occurs despite a vigorous sympathetic nervous system response. Drug classes commonly employed by cardiologists such as diuretics, nitroglycerin, calcium channel blockers (CCB), and certain b-blockers, also pharmacologically antagonize the autonomic system via preload depletion or vasodilation.
In patients with severe CHF who are fluid overloaded, assuming an upright position can prompt a paradoxical effect. Decreasing venous return can increase the cardiac output in these patients by decreasing a right to left ventricular septal bulge. Therefore, in the upright position, the baroreceptors are not activated, and further sympathetic nervous system engagement is not triggered [15] .
DIAGNOSIS
Supine-stand test
The easiest and most important diagnostic test to evaluate orthostatic hypotension is to measure the orthostatic change in BP from a supine position to a standing position. The SBP, DBP, and HR should be recorded after the patient has remained in the supine position for at least 5 min. Upon standing, the BP and HR should be taken at 1, 3, and 5 min after standing. Orthostatic hypotension is present if there is a drop in any BP parameter (either SBP or DBP) that meets the aforementioned criteria at the 3 or the 5-min mark [10 & ]. The 1-min values can be used if the patient cannot stand long enough for a 3-min standing BP reading. Some studies suggest extending the test period to 10 min will increase the sensitivity to diagnose a milder form of orthostatic hypotension, 'delayed orthostatic hypotension' [16] . If orthostatic hypotension is present, the change in HR can be utilized to differentiate between nOH and non-nOH. An increase in HR more than 20 bpm suggests a non-nOH cause, whereas an increase in HR less than 15 bpm suggests a nOH cause [10 & ].
In scenarios where a supine-stand test is not feasible, a sit-stand test can be more convenient and has been recommended as an initial screening tool in these cases [10 & ]. An orthostatic threshold drop of at least 15 mmHg SBP or at least 7 mmHg DBP has been shown to have the greatest sensitivity and specificity for identifying orthostatic hypotension in this setting [17 & ].
Workup and interpretation
When both BP and HR are consistent with a diagnosis of nOH, a careful review of the patient's medical history should be undertaken to rule out nonautonomic causes of a blunted chronotropic response to standing [10 & ]. A cardiologist is well suited to rule out these causes as several cardiac conditions and medications can be culprits.
An initial 12-lead ECG should be performed to rule out sinus nodal disease, atrioventricular block, or any other conduction abnormalities [1] . If a patient has a pacemaker, the device should be interrogated to ensure it is functioning correctly and settings are appropriate. For example, patients with chronic atrial fibrillation and complete atrioventricular block with a single ventricular lead will not be able augment their HR when standing (unless their accelerometer is turned on) and may be more vulnerable to orthostatic hypotension. A diagnosis of nOH can be made only when other causes of a blunted chronotropic response are ruled out in the setting of orthostatic hypotension (see next paragraph). Patients may be particularly sensitive to preload depletion with diuretics or nitrates. Cardiac medications with potent negative chronotropic effects such as b-blockers and potent vasodilators such as hydralazine, a-1 antagonists, or dihydropyridine (DHP) CCB (e.g., amlodipine or nifedipine) should be scrutinized. Noncardiac medications such as tamsulosin (an a-1 antagonist used for prostatic hypertrophy), morphine, or antipsychotic drugs should also be identified [18] .
Head-up tilt table testing
A head-up tilt table test is not always widely available, and is not mandatory to make a diagnosis of nOH [10 & ]. It consists of a platform that allows the patient to be strapped in securely where they can have continuous and simultaneous BP and HR monitoring. The table is then tilted to 60-808 head up (so that patient is almost standing up) after baseline parameters are obtained [13] . It is very useful for individuals who are at high risk (known neurodegenerative disease or long-standing uncontrolled diabetes mellitus) and are persistently symptomatic but have only borderline orthostatic parameters on a supine-stand test.
TREATMENT/MANAGEMENT
Medication use review
The adjustment or discontinuation (when feasible) of medications that predispose to orthostatic hypotension is the initial intervention of choice to treat orthostatic hypotension [10 & ,18] Fig. 2 . A substantial number of these offending agents are medications that cardiologists use on a daily basis. Orthostatic tachycardia in the setting of orthostatic hypotension strongly suggests a hypovolemic state and should prompt reevaluation and adjustment of diuretic therapy [2 && ]. b-blockers with significant a-1 receptor antagonism such as carvedilol and labetalol are notorious for worsening orthostatic hypotension because of the combination of negative inotropic effects from b-1 receptor blockade as well as impaired vasoconstriction from vascular smooth muscle a-1 receptor blockade. In cases where b-blockers administration is essential, switching these b-blockers with a-1 receptor antagonism to a pure b-blocker is warranted. In contrast to b-blockers, DHP CCB have few mandatory indications and should be best avoided because of their potent vasodilatory effects. In certain cases, such as vasospastic angina, where a CCB can be a useful adjunct, DHP CCB should be switched to verapamil or diltiazem because of less vasodilatory effects and the availability of a shorter duration of action formulation, which can allow for drug-free periods during the day when the patient is most symptomatic from orthostatic hypotension. Similarly, nitrates should be avoided during the day to avoid excessive daytime venodilatation during the day. Nitrates should be preferentially be given during the night. Finally, a-1 antagonists such as terazosin and doxazosin, especially if administered for HTN, should be replaced by other antihypertensive medications, such as angiotensin converting enzyme inhibitors or angiotensin-receptor blockers, which are often better tolerated in these patients. If the indication is for benign prostatic hypertrophy, a hormonal agent such as a 5a-reductase inhibitor is preferable to an a-1 antagonist such as tamsulosin.
Nonpharmacologic interventions
There are several nonpharmacologic interventions that can be used alone, but also in conjunction with pharmacologic agents [2 . In patients without CHF, patients can be instructed to add one to two teaspoons of salt daily to their diet to increase fluid retention, and expand the blood volume. The adequacy of salt intake can be assessed by checking 24-h urinary sodium excretion, which should be more than 150 mEq when at steady state in the absence of diuretics [10 & ]. We often recommend both the osmopressor response and dietary salt and water expansion as a part of the initial therapy. Compression garments, including abdominal binders, are especially valuable interventions in patients with heart failure who are fluid restricted. Abdominal binders with mild pressure compression (10 mmHg) or waist-high stockings (in contrast to knee high stockings which are not as effective) of at least 30-mmHg blunt orthostatic BP drop and improve symptoms [10 & ,21] . In fact, a recent study showed that abdominal compression of 40 mmHg was as effective as midodrine [22 & ]. One challenge with abdominal binders is that patients may find it difficult to make them tight enough to generate an adequate compression.
Pharmacologic interventions
There are a number of pharmacologic agents commonly used to treat orthostatic hypotension, but only two are United States Food and Drug Administration (FDA) approved: midodrine and droxidopa. Midodrine was approved by the FDA in 1986 and is the most commonly used pharmacologic agent for orthostatic hypotension [18,23 & ]. Midodrine is a prodrug whose metabolite is an a-1 adrenergic agonist. Time to peak concentration is roughly 1 h and the pharmacological effects last up to 4-5 h [18, 24] . A recent phase 4 study in 33 patients demonstrated that midodrine administration, on average, delayed onset of syncopal or presyncopal symptoms during head- Droxidopa was recently approved by the FDA after three randomized double-blind studies demonstrated impressive improvement in both symptoms as well as BP parameters [25] . Droxidopa is a well tolerated, synthetic prodrug of norepinephrine, reaching peak plasma concentration in 2 h [26, 27] . Droxidopa can be dosed at 100-600 mg/doses, given 2-3 times/day [18] . However, access to this medication is an issue because it is not yet approved in Europe or Canada.
Fludrocortisone is a synthetic aldosterone analogue that treats orthostatic hypotension via sodium and water retention. Recently, an oral dose of 0.1 mg twice daily (0.2 mg/day in total) was shown to decrease the DBP drop with standing in orthostatic hypotension patients by 37% [28] . This agent should be cautiously used in patients with CHF, and the dosage ranges from 0.05 to 0.3 mg. Higher doses have the potential to suppress the hypothalamic-pituitary axis and glucocorticoid side-effects [18] .
Pyridostigmine, an acetylcholinesterase inhibitor that putatively works by augmenting cholinergic tone at the autonomic ganglion thereby increasing residual sympathetic tone, is not considered a firstline agent, but stands out from other agents in that it neither causes significant vasoconstriction nor does it cause fluid retention, making it ideal for patients with CHF [18, 28] . However, it only has modest effects on standing BP and a recent study showed that it was no more effective than placebo in decreasing DBP drop with standing [28] . It can be very effective in increasing bowel motility in patients with autonomic failure, who are often prone to severe constipation [10 & ]. Octreotide, erythropoietin, yohimbine, atomoxetine are other pharmacologic agents used for the treatment of orthostatic hypotension; they have less robust data to support their use, should be considered second-line pharmacologic agents for the treatment of orthostatic hypotension, and should not be routinely prescribed by the cardiologist without additional expertise in managing these patients.
TREATMENT OF CONCURRENT SUPINE HYPERTENSION
The simultaneous treatment of orthostatic hypotension during the day and supine HTN at night requires implementing key nonpharmacologic measures as well as understanding the unique pharmacokinetic profiles of the various agents involved, namely short-acting vasoconstrictors (midodrine or droxidopa) and short-acting antihypertensives (e.g., nitroglycerin patch, losartan, or eplerenone; Table 1 ).
The effects of antihypertensive medications should only be limited to nighttime, when the patient is supine. Therefore, antihypertensives should be administered shortly prior to bedtime, and ideally effects should wear off the next morning prior to the patient rousing. The benefit of using a nitroglycerin patch is that the antihypertensive effect of transdermal nitroglycerin dissipates shortly after it is removed. The effects of eplerenone 50 mg, when administered at 8 p.m., maximally reduced BP at 4 a.m., with near return to baseline at 8 a.m. [29] . Losartan at 50 mg has been shown to decrease supine HTN and not worsen orthostatic hypotension in the morning [13] . At night, the patient should sleep with the head of the bed tilted up to both decrease supine HTN and also minimize nocturnal supine pressure diuresis, which will obviously worsen orthostatic hypotension the next morning [10 & ]. One concern is that patients on antihypertensive medications at night might be at higher risks of falls if they have nocturia and get up to void at night. Risk mitigation strategies could include the use of a urinal at night, a bedside commode chair, or even intermittent bladder self-catheterization in some cases.
In the morning, any nitroglycerin patches should be removed prior to getting up. The patient should then take a short-acting vasoconstrictor (midodrine or droxidopa) along with 500 ml of free water (ingested within 2-3 min to exploit the osmopressor phenomenon) [3 & ]. During daytime, the patient should also wear an abdominal binder or waist-high compression garments [10 & ].
EXPECTED CLINICAL RESPONSE AND PROGNOSIS
Patients with reversible causes of orthostatic hypotension usually do very well after the culprit is identified and rectified. However, patients with nOH often have only a modest improvement in symptoms after institution of these measures (Table 1) . This improvement tends to diminish over time with progression of disease. Furthermore, after a diagnosis of autonomic failure, 34% of individuals 'phenocovert' to MSA or dementia with Lewy bodies/Parkinson's disease within 10 years [30] , and this is associated with a poorer prognosis when this occurs. Median survival after MSA diagnosis is 6-7 years, and 11-12 years for those with Parkinson's disease and orthostatic hypotension [31] . Individuals with nOH secondary to diabetes mellitus also do not fare well, with a 10-year mortality estimated to be upwards of 32% [5] .
CONCLUSION
Given the strong association between orthostatic hypotension and cardiovascular disease, the cardiologist plays an important role in the recognition and management of orthostatic hypotension patients. Unfortunately, the prognosis of nOH is poor. Therefore, the goal for management of these patients from a cardiologist standpoint is to minimize symptoms and improve quality of life, while simultaneously optimizing cardiovascular risk within their expected lifetime horizon [13] . TID, three times per day.
